6 recruiting, 6 unknown, 3 completed, 2 active not recruiting. 8 Phase 1, 3 Not applicable, 2 Phase 2, 2 Phase 3.
Follow Malignant Neoplasms: new trials by email Literature Review of Malignant Neoplasms trials Research Report on Malignant Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Body Composition and Setup Errors in Radiotherapy Malignant Neoplasms | Not yet recruiting | Shijiazhuang People's Hospital | 150 | 2026-07-01 | 2026-06-30 | |
| Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures RonovoTM Robotic Surgical Platform - Malignant Neoplasms, Cancer | Not applicable | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 40 | 2026-06-19 | 2026-09-22 |
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2026-03-23 | 2026-10-21 |
| Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors YKYY031 group (the first stage), YKYY031 group (the second stage) - Malignant Neoplasms | Phase 1 | Recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 76 | 2026-03-10 | 2026-10-13 |
| An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma SLC-3010 + Axitinib, Axitinib - Clear Cell Renal Cell Carcinoma, Neoplasms | Phase 2 | Recruiting | Yonsei University | 78 | 2026-03-01 | 2026-03-13 |
| A Study of DEG6498 in Participants With Solid Tumors DEG6498 - Malignant Neoplasms | Phase 1 | Recruiting | Degron Therapeutics Co. | 100 | 2025-11-13 | 2026-06-30 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors PF-07799544, PF-07799933 - Melanoma, Glioma | Phase 1 | Active not recruiting | Pfizer | 148 | 2022-11-30 | 2026-09-01 |
| A Multi Center Study of Sexual Toxicities After Radiotherapy No intervention - Malignant Neoplasms | Recruiting | Icahn School of Medicine at Mount Sinai | 300 | 2022-10-04 | 2026-06-22 | |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors BPI-421286 - Malignant Neoplasms, Metastatic Cancer | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 80 | 2021-08-24 | 2022-04-07 |
| A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer SCART radiation therapy - Malignant Neoplasms | Phase 1 | Unknown | Baptist Health, Louisville | 12 | 2021-06-05 | 2021-05-11 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement PF-07284890, Binimetinib, Midazolam - Malignant Melanoma, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Pfizer | 65 | 2021-01-08 | 2025-10-23 |
| A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors IMMH-010 - Malignant Neoplasms | Phase 1 | Unknown | Tianjin Chasesun Pharmaceutical Co., LTD | 96 | 2020-05-14 | 2023-11-09 |
| The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients Flora analysis - Lung Cancer, Breast Cancer | Unknown | The First Affiliated Hospital of Dalian Medical University | 500 | 2019-12-20 | 2019-12-18 | |
| Validation of the Italian Version of the PRO-CTCAE PRO-CTCAE items - Malignant Neoplasms | Unknown | National Cancer Institute, Naples | 3675 | 2018-07-01 | 2023-03-24 | |
| Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases Naderin, Standard Therapy - Malignant Neoplasms, Tuberculosis (TB) | Phase 2 / Phase 3 | Completed | MIPO Clinic | 75 | 2013-05-15 | 2026-06-30 |
| Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent biliary stent - Biliary Stricture, Malignant Neoplasms | Not applicable | Terminated | Jong Taek, Lee | 74 | 2011-09-01 | 2020-03-11 |
| Community Cancer Centers Pilot Patient Survey Malignant Neoplasms, Cancer | Completed | National Cancer Institute (NCI) | 3955 | 2008-11-03 | 2019-12-17 | |
| Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent Biliary stent - Biliary Stricture, Malignant Neoplasms | Not applicable | Completed | Taewoong Medical Co., Ltd. | 106 | 2007-02-01 | 2020-03-11 |
| Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease Malignant Neoplasms, Hereditary Neoplastic Syndromes | Recruiting | National Cancer Institute (NCI) | 5950 | 1998-03-12 | 2026-10-26 |
Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Melanoma (3) · Pancreatic Neoplasms (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Kidney Neoplasms (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Thyroid Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1)
Neoplasms by Site (8) · Digestive System Diseases (5) · Lung Diseases (5) · Neoplasms by Histologic Type (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Thoracic Neoplasms (5) · Digestive System Neoplasms (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Gastrointestinal Diseases (4)
Axitinib (1) · Midazolam (1) · Nivolumab (1) · PF-07284890 (1) · Standard of Care (1) · belzutifan (1) · binimetinib (1) · cabozantinib (1) · lenvatinib (1) · pembrolizumab (1) · sodium nucleinate (1)
National Cancer Institute (NCI) (2) · Pfizer (2) · Baptist Health, Louisville (1) · Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (1) · Betta Pharmaceuticals Co., Ltd. (1) · Carisma Therapeutics Inc (1) · Degron Therapeutics Co. (1) · Icahn School of Medicine at Mount Sinai (1) · Instituto do Cancer do Estado de São Paulo (1) · Jong Taek, Lee (1) · MIPO Clinic (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute, Naples (1) · Shijiazhuang People's Hospital (1) · Taewoong Medical Co., Ltd. (1)
United States (8) · China (7) · South Korea (4) · Brazil (3) · Canada (3) · Israel (3) · Australia (2) · Japan (2) · Belgium (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1)
Dong Ki Lee, Ph.D (2) · Chaoxing Liu, Dr (1) · Deborah C Marshall, MD MAS (1) · Don Haeng Lee, Ph.D (1) · Francesco Perrone, MD, PhD (1) · Ho Gak Kim (1) · Irene P Prabhu Das, Ph.D. (1) · Jeanett Wetzel (1) · Mung Whan Kim, Ph.D (1) · Sang Heum Park (1) · W. Marston Linehan, M.D. (1) · Yilong Wu (1)
PMID 34234673, PMID 36441083, PMID 37404084, PMID 39059033, PMID 39077892, PMID 39726590, PMID 39920391
2025 (1)